Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (17500)	8/2/2003 12:10:45 PM
From: Spekulatius	Read Replies (4) \| Respond to of 78476

Portfolio update - NHY, E, APC, JNJ, NRGN I sold my remaining position in NHY. The stock seems fully valued now. I am considering to take a new position in the oil sector. My current favorites are E (the italian multinational) and APC. I don't have a position yet. I bought a first position in JNJ. Not super cheap but reasonably priced. PE about 19. AAA credit rating, very clean balance sheet and stellar LT record. Chart looks good as long as 50$ resistance hold, IMO. The stock is weak because of the botched coated stent rampup. I still bet that JNJ will solve the problems (after all the product is approved) and that this will be a multi billion dollar product. I am looking to buy more on weakness. I bought a speculative position in NRGN, a small biotech outfit trading at moderate premium to cash. NRGN is specialized in neuro/brain drugs and has a couple of molecules in the clinic. All of them address big markets. the flipside is that the company has been in drug development business forever and never came beyond Phase II so far.